Phase 1 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given documented, informed consent to take part in the study.
• People who are willing to allow the study team to access and use existing stored tissue samples, if those samples are available.
• People aged 18 or older.
• People whose general physical functioning is rated at a level where they are able to carry out basic daily activities (a score of 2 or less on a standard medical scale called the ECOG scale — confirm with trial site if unsure what this means for a specific situation).
• People with a life expectancy of more than 3 months.
• People with a solid tumour (a type of cancer that forms a lump or mass) whose cancer has not responded to standard treatments, or who have chosen not to have standard treatments. Note: for one specific group in the trial involving a particular type of lung cancer (NSCLC) and a specific drug combination, people whose cancer has been stable or improved on a certain targeted therapy for at least 2 months may be eligible (confirm with trial site).
• People of childbearing potential (both male and female) who agree to use an adequate non-hormonal form of contraception, or to abstain from heterosexual activity, during the study and for 30 days after the last dose of the study drug.
• People whose recent blood test results (taken within 14 days before starting the trial) show that their immune cell counts, platelet levels, liver function, and kidney function all fall within the ranges required by the trial.
• Women of childbearing potential who have a negative pregnancy test before starting the trial.

Who may not be able to join:

• People who are currently taking dietary or herbal supplements.
• People who are currently taking other experimental treatments or chemotherapy (an exception may apply for people in the lung cancer group taking a specific targeted therapy — confirm with trial site).
• People who are currently taking the blood-thinning medication warfarin.
• People who are currently taking or planning to take medications that are known to interact with a specific liver enzyme pathway called CYP3A4, CYP2C9, or CYP3A (confirm with trial site or treating doctor which medications this applies to).
• People who have difficulty taking oral (swallowed) medication — for example, those who cannot swallow tablets, have absorption problems in the gut, or have ongoing nausea or vomiting.
• Women who are pregnant, planning to become pregnant, or currently breastfeeding.
• People with a known allergy to any ingredient in the study drug or drugs being used in the trial.
• People who have had another cancer in the past, unless it was: a certain type of treated skin cancer (basal cell or squamous cell), cervical cancer that had not spread, a Stage I or II cancer that is now in full remission, or any cancer from which the person has been cancer-free for at least three years.
• People with an existing or past medical condition that the trial doctor believes would increase the risk of taking part in the study.
• People who, in the trial doctor's opinion, may not be able to follow all of the study procedures and requirements.

Important: Always verify eligibility with the trial site directly before applying.